This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
183 children were empirically treatedwith ceftriaxone and amikacin in a single daily dose, with 96 (52%) having absolute granulocyte count less than 100/mm3 at the onset, 68 (37%) were affected by acute leukemia or lymphoma, 3 (1%)by chronic leukemia, 94 (51%) by solid tumours and 21 (11%) patients underwent bone marrow transplantation. The mean age of study subjects was 6.5 years (1-17). There were 105 males (57.4%) and 78 females (42.6%) involved in the study. The mean weight was 24.8kg (3.9-68).
Study design
The study was a retrospective cohort study.
Analysis of effectiveness
The analysis of the clinical study was based on the whole sample. Primary health outcomes were based around response rates for:
(1) bacteremic patients (n=20), Further, assessments of effectiveness were carried out on patients with peripheral polymorphonucleates (PMN) count cells/mm3 <100 (n=88), and 100-500 (n=77).
Effectiveness results
Response rates were:
(1) bacteremic patients,60%; Ceftriaxone plus amikacin was effective in 135/183 (74%) patients with a median time defervescence of 3 days (1-11). 70% of subjects with a PMN cell count/mm3 <100 responded to the therapy, and 77% of those subjects with a PMN cell count/mm3 100-500 also responded to the therapy. Note: The initial antibiotic regimen was discontinued due to side-effects (cutaneous eruption allergic reactions) experienced by 3 patients.
Clinical conclusions
Once daily ceftriaxone plus amikacin should remain as the standard regimen for the empirical treatment of febrile granulocytopenic children suffering from cancer.
Measure of benefits used in the economic analysis
Benefits were expressed in costs.
Direct costs
No discounting was required. Quantities and costs were not analysed separately. The cost boundary adopted appears to be that of a health service provider. No prices were stated.
